Suomi - suomi - Fimea (Suomen lääkevirasto)

teva finland oy - ranitidini hydrochloridum - poretabletti - 300 mg - ranitidiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

glaxosmithkline oy - ranitidini hydrochloridum - poretabletti - 75 mg - ranitidiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - ranitidini hydrochloridum - poretabletti - 300 mg - ranitidiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - sucralfate - tabletti - 1 g - sukralfaatti

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - sucralfate - oraalisuspensio - 200 mg/ml - sukralfaatti

Suomi - suomi - Fimea (Suomen lääkevirasto)

oy simcere europe ltd. - diosmectite - jauhe oraalisuspensiota varten - 3 g - diosmektiitti

Suomi - suomi - Fimea (Suomen lääkevirasto)

kappler pharma consult gmbh - itopride hydrochlorid - tabletti, kalvopäällysteinen - 50 mg - itopridi

Euroopan unioni - suomi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - atsakitidiini - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiset aineet - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Euroopan unioni - suomi - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - atsakitidiini - leukemia, myeloidi, akuutti - antineoplastiset aineet - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Euroopan unioni - suomi - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiset aineet - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.